UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer

Key Takeaways

• AI pathway launched in North East Essex primary care
• Targets early detection of oesophageal and gastric cancers
• Uses C the Signs platform analyzing EHR and patient data
• Patients invited via SMS for digital risk assessment
• Aligns with England’s National Cancer Plan for proactive case finding

Summary

A new NHS‑first AI‑enabled case‑finding pathway has launched in North East Essex to detect oesophageal and gastric cancers earlier. The programme, built on the C the Signs platform, analyses routine electronic health records and patient‑reported data to flag high‑risk individuals. Eligible patients receive SMS invitations for a digital risk assessment and are fast‑tracked to diagnostics such as capsule sponge testing, endoscopy or CT scans. The initiative aligns with England’s National Cancer Plan and aims to shift cancer detection from reactive to proactive, improving outcomes and easing hospital pressure.

Pulse Analysis

The United Kingdom has long struggled with late‑stage diagnoses of upper‑gastrointestinal malignancies, as oesophageal and stomach cancers lack a national screening programme and often present with vague symptoms. Early detection dramatically improves survival, yet four‑in‑five cases are identified at an advanced stage. Leveraging artificial intelligence to sift through routine electronic health records offers a way to flag high‑risk patients before symptoms become critical. The new AI‑enabled case‑finding pathway in North East Essex represents the first population‑level deployment of such technology in English primary care, signalling a shift toward data‑driven preventive oncology.

Built on the C the Signs platform, the pathway analyses both clinician‑entered data and patient‑reported information to generate a risk score. Eligible individuals receive an SMS invitation to complete a brief digital questionnaire; those flagged as high risk are fast‑tracked to appropriate investigations such as capsule sponge testing, endoscopy or CT scanning. GP Primary Choice coordinates the rollout across more than 1,500 practices, ensuring neighbourhood‑level consistency and scalability. By embedding AI decision support directly into the electronic health record, clinicians gain actionable insights without additional testing, accelerating referrals and potentially reducing diagnostic delays.

The initiative dovetails with England’s National Cancer Plan, which calls for predictive, risk‑based pathways and greater use of health‑data analytics. If successful, the model could be replicated for other cancers lacking screening programmes, easing pressure on acute hospitals and delivering diagnostics closer to patients’ homes. AstraZeneca’s involvement underscores pharmaceutical interest in early‑diagnosis ecosystems that can feed into later‑stage therapeutic interventions. As AI adoption expands across the NHS, the partnership demonstrates how public‑private collaboration can accelerate innovation while maintaining clinical safety through UKCA‑marked medical devices.